PureTech Health PLC Stock Analysis
| PRTC Stock | USD 16.86 -0.36 -2.09% |
200 Day MA 17.6303 | 50 Day MA 17.7627 | Beta 0.688 |
Macro event markers
PureTech Health PLC appears overvalued based on a Real Value estimate of $14.39 and a Target Price of $46.0. This stock analysis focuses on estimating intrinsic value. This frames what PureTech Health PLC could be worth beyond short-term market pricing. Coverage is split between fundamental metrics and technical price analysis. Each method adds a different lens on value and price action.
PureTech Health PLC holds a debt-to-equity ratio of 0.083. Short Term Debt is evolving in line with broader financial reporting trends. Last year, PureTech Health recorded Short Term Debt of 8.84 Million. Per market data dated March 13, 2026, Short and Long Term Debt is projected to grow to approximately 6.6 M, whereas our analysis places Net Debt near about -244.1 M following downward revisions. Rising leverage can increase PureTech Health's financial risk sensitivity. Interest payments can affect earnings and coverage ratios over time. Asset vs Debt
Equity vs Debt
Price Book 1.1139 | Enterprise Value Ebitda 2.7957 | Price Sales 65.153 | Shares Float 166.9 M | Wall Street Target Price 46 |
PureTech Health PLC reported a decline of $100.0 million in Net Income, $27.8 million in Net Income, and a net loss attributable to common shareholders of $66.2 million.
Supplementary financial insights are provided in Interest Expense and Depreciation And Amortization.
Stock Analysis Notes
The company has price-to-book ratio of 1.11. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. PureTech Health PLC had not issued any dividends in recent years. PureTech Health PLC reported $602.6 million in Total Assets, a Return On Assets of 8.4%, and a Return On Tangible Assets of 8.4%.Total Assets | 554.02 Million |
Investor Insights and Alerts
Automated alerts tied to PureTech Health PLC help investors surface material conditions that may support or challenge the current thesis before they become expensive mistakes. In practice, the value comes from seeing which signals are new, which are persistent, and which are strong enough to justify action.
| PureTech Health PLC currently holds about 368.03 M in cash with -134.37 M of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 12.84. | |
| Latest headline from news.google.com: PureTech Health Stock Crosses Below 50-Day Moving Average - Whats Next - MarketBeat |
Largest EPS Surprises
Analyst estimates for PureTech Health are built from management guidance, sector trends, and macro assumptions. When actual EPS deviates significantly, the market recalibrates its forward view quickly. For this stock, read EPS surprises with profitability quality and forward revisions.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2023-04-28 | 2023-03-31 | -1.76 | -0.08 | 1.68 | 95 | ||
2024-04-25 | 2024-03-31 | -1.98 | -0.24 | 1.74 | 87 | ||
2022-04-26 | 2022-03-31 | -2.55 | 0.05 | 2.6 | 101 |
Environmental, Social, and Governance (ESG) Scores
ESG analysis for PureTech Health PLC is not only about values-based screening; it can also highlight operating practices and governance choices with real financial consequences. These scores become more relevant when they are compared against peers facing similar regulatory, labor, and supply-chain pressures.
Top Institutional Investors Holding PureTech Stock
Institutional ownership matters in PureTech Health PLC because pension funds, mutual funds, banks, and advisers can materially influence liquidity, governance, and price discovery. Used correctly, institutional data helps investors understand who may be setting the marginal price and how resilient that holder base could be under stress.
| Shares | Lansdowne Partners Limited Partnership | 2025-09-30 | 14.1 M | Pentwater Capital Management Lp | 2025-12-31 | 70 K | Millennium Management Llc | 2025-09-30 | 17.8 K | Diadema Partners Lp | 2025-09-30 | 7.3 K | Persistent Asset Partners Limited | 2025-12-31 | 1.8 K | Ubs Group Ag | 2025-09-30 | 20.0 | Portolan Capital Management, Llc | 2025-09-30 | 0.0 | Atlantic Union Bankshares Corp | 2025-09-30 | 0.0 | Birch Hill Investment Advisors Llc | 2025-09-30 | 0.0 | Sbi Securities Co Ltd | 2025-12-31 | 0.0 |
Market Capitalization
PureTech Health PLC remains a small-cap name by market cap, with total market value estimated at 416.39 M versus biotechnology companies. Useful market capitalization details here include about 24.18 M shares outstanding, enterprise value near 105.74 M, and a workforce of about 56 people.Profitability
Profitability analysis for PureTech Health PLC should focus on how efficiently revenue converts into operating income, net income, and ultimately free cash flow that can be reinvested or returned to shareholders. Annual revenue is about 4.83 Million. Investors should compare gross, operating, and net margins rather than relying on one headline figure.
The company has Profit Margin (PM) of 7.93 %, which may reflect a scalable business model with improving unit economics. This is above the expected range for the sector. Similarly, it shows Operating Margin (OM) of -25.9 %, which means operating inefficiencies are consuming more than the revenue earned. | Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | 0.08 | 0.08 | |
| Return On Capital Employed | -0.28 | -0.26 | |
| Return On Assets | 0.08 | 0.08 | |
| Return On Equity | 0.15 | 0.09 |
Management Efficiency
The company has return on total asset (ROA) of -12.95 % which means that on every $100 spent on assets, it lost $12.95. This is very low relative to industry peers. Similarly, it shows a return on stockholder's equity (ROE) of 9.44 %, which means that for every $100 of equity, $9.44 was returned as profit.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 13.62 | 9.34 | |
| Tangible Book Value Per Share | 13.59 | 9.20 | |
| Enterprise Value Over EBITDA | 5.77 | 6.05 | |
| Price Book Value Ratio | 1.08 | 1.13 | |
| Enterprise Value Multiple | 5.77 | 6.05 | |
| Price Fair Value | 1.08 | 1.13 | |
| Enterprise Value | 551.6 M | 528.1 M |
When investors examine management execution at PureTech Health PLC, they are looking for evidence that strategy, financial discipline, and operating results are moving in the same direction. The business currently sits in the Healthcare sector and the Biotechnology industry. Current market capitalization is about 416.39 Million, enterprise value is near 105.74 Million, and annual revenue is around 4.83 Million.
Operating Margin | Three Month Return -0.30 | Short Long Term Debt Total | Ten Year Return -56.21 | Three Year Return -40.63 |
Technical Drivers
As of the 13th of March 2026, PureTech Health is marked at 16.86 per share. Recent trend indicators show Variance of 7.25, risk adjusted performance of -0.01, and Coefficient Of Variation of -3,966. Trend analytics rely on normalized volatility and volume metrics. Trend metrics are reviewed within historical sector ranges.PureTech Health PLC Price Movement Analysis
The output start index for this execution was twenty-three with a total number of output elements of thirty-eight. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. PureTech Health middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for PureTech Health PLC. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.
Outstanding Bonds
Reviewing PureTech Health PLC bond obligations helps investors understand how much of the business is financed with fixed-income capital rather than purely with equity. This is why bond analysis is not just a credit exercise; it also informs equity holders about solvency, optionality, and future capital-allocation pressure.
Predictive Daily Indicators
Daily trading signals in PureTech Health PLC help active traders monitor momentum, reversals, and volume pressure while the session is still developing. The better setups usually come from combining these signals with strict risk limits, because short-term data can reverse quickly when liquidity thins.
Corporate Filings
6K | 18th of December 2025 A report filed by foreign private issuers with SEC. A foreign private issuer is a non-U.S. company with securities traded on U.S. exchanges. | ViewVerify |
6K | 10th of December 2025 A report filed by foreign private issuers with SEC. A foreign private issuer is a non-U.S. company with securities traded on U.S. exchanges. | ViewVerify |
6K | 28th of August 2025 A report filed by foreign private issuers with SEC. A foreign private issuer is a non-U.S. company with securities traded on U.S. exchanges. | ViewVerify |
13A | 11th of August 2025 The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934 | ViewVerify |
6K | 16th of July 2025 A report filed by foreign private issuers with SEC. A foreign private issuer is a non-U.S. company with securities traded on U.S. exchanges. | ViewVerify |
6K | 8th of July 2025 A report filed by foreign private issuers with SEC. A foreign private issuer is a non-U.S. company with securities traded on U.S. exchanges. | ViewVerify |
6K | 16th of June 2025 A report filed by foreign private issuers with SEC. A foreign private issuer is a non-U.S. company with securities traded on U.S. exchanges. | ViewVerify |
6K | 30th of April 2025 A report filed by foreign private issuers with SEC. A foreign private issuer is a non-U.S. company with securities traded on U.S. exchanges. | ViewVerify |
Forecast Models
Quantitative forecast tools for PureTech Health PLC focus on patterns in observed data, which makes them especially useful when the market is moving faster than traditional bottom-up research can refresh. Used well, forecast models can complement fundamental research by showing where observed price behavior still supports or contradicts the discretionary thesis.Debt to Cash Allocation
The debt-to-cash mix for PureTech Health helps explain how management balances flexibility and funding cost through a business cycle.
PureTech Health PLC currently holds $22.36 M in liabilities with Debt to Equity (D/E) ratio of 0.08, which may suggest PureTech Health PLC is not taking enough advantage from borrowing. PureTech Health PLC has a current ratio of 2.49, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about PureTech Health's use of debt, we should always consider it together with its cash and equity.Total Assets Over Time
Assets Financed by Debt
The debt-to-assets ratio shows the degree to which PureTech Health uses debt to finance its assets. It includes both long-term and short-term borrowings maturing within one year. It also includes both tangible and intangible assets, such as goodwill.PureTech Health Debt Ratio | 6.47 |
Corporate Bonds Issued
Bond maturity for PureTech Health is a core risk dimension. Longer duration can offer higher yield, but price sensitivity and credit uncertainty also increase.
PureTech Short Long Term Debt Total
Short Long Term Debt Total | 26.03 Million |
Stock Analysis Methodology
As a small-cap equity, PureTech Health is evaluated on earnings consistency, capital structure, and technical price behavior. PureTech Health trades at P/B of 1.11, P/S of 65.15. Profitability metrics show ROE of 9.44%, net margin of 7.93%, operating margin of -25.9%. Balance sheet indicators include debt-to-equity of 0.08 and current ratio of 2.54. Financial distress probability is estimated at 23%, indicating low near-term solvency risk. RSI at 46 is in neutral territory. A beta of 0.2926 indicates low sensitivity to broad market moves. Sharpe ratio of 0.011 reflects the risk-adjusted return profile. PureTech Health has a market cap of 416.39 M, ROE of 9.44%.
Unless otherwise specified, data for PureTech Health PLC is compiled from periodic company reporting and market reference feeds and standardized for comparability. Updates may occur throughout the day.
This content is curated and reviewed by:
Raphi Shpitalnik - Junior Member of Macroaxis Editorial BoardCurrent PureTech Analyst Rating Consensus
| Target Price | Consensus | # of Analysts | |
| 46.0 | Strong Buy | 2 | Odds |
The summary for PureTech Health PLC includes current and past analyst recommendations. It also summarizes the average analyst consensus. Consensus analyst estimates for PureTech represent the average of individual forecasts, which can mask significant disagreement. High forecast dispersion for PureTech Health PLC suggests genuine analytical uncertainty about future results and may indicate elevated event risk.
PureTech Stock Analysis Indicators
Diagnostics snapshot includes 17 indicators such as Begin Period Cash Flow, Common Stock Shares Outstanding, Total Stockholder Equity.
| Begin Period Cash Flow | 191.1 M | |
| Common Stock Shares Outstanding | 27 M | |
| Total Stockholder Equity | 414.7 M | |
| Total Cashflows From Investing Activities | 240.9 M | |
| Tax Provision | -4 M | |
| Quarterly Earnings Growth Y O Y | 0.615 | |
| Property Plant And Equipment Net | 15.1 M | |
| Cash And Short Term Investments | 367.3 M | |
| Cash | 280.6 M | |
| Accounts Payable | 5.5 M | |
| Net Debt | -258.3 M | |
| 50 Day M A | 17.7627 | |
| Total Current Liabilities | 41.4 M | |
| Other Operating Expenses | 140.4 M | |
| Non Current Assets Total | 216.4 M | |
| Non Currrent Assets Other | 476 K | |
| Stock Based Compensation | 22.9 M |
Popular Tools for PureTech Stock analysis
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Portfolio Prophet Use AI to generate optimal portfolios and find profitable investment opportunities |